Pre-solicitationPosted Jan 2, 2025·Responses due Jan 9, 2025

6550--Notice of Intent to Sole Source - Minneapolis VA Medical Center - FDA-Approved Microgenics DRI Ecstasy Plus Assay Reagent used with Beckman AU480 Analyzers

Veterans Affairs · NETWORK CONTRACT OFFICE 23 (36C263)

Stage
Early notice (sources sought, presolicitation or special notice)
NAICS
325413
Value
Not stated
Solicitation
36C26325Q0328
Set-aside
None stated
PSC
6550
Place
Minneapolis, MN, USA
Contact
Alisha Milander (Alisha.Milander@va.gov)
Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 36C26325Q0328 in this department, oldest first.

Early notice
  • Jan 2, 2025 · this notice
    Pre-solicitation
Solicitation
None posted
Award
  • Jan 10, 2025
    Award Notice
    MICROGENICS CORPORATION · $82K
    Open

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Answer the notice: this is when the requirement can still be shaped.
  • Contact the contracting officer named on the notice.
  • Check who won similar work; they are the likely bidders.

What the notice says

This Notice of Intent is provided to advise that the Government intends to solicit and negotiate a sole source, Firm Fixed Price contract with option periods with only one source, Microgenics Corporation, to provide FDA-Approved Microgenics DRI Ecstasy Plus Assay Reagent used with Beckman AU480 Analyzers for the Minneapolis VA Medical Center. This contract action is for supplies for which the Government intends to solicit and negotiate a Sole Source award under the authority of FAR 13.106-1. This notice of intent to award a sole source contract is not a request for competitive proposals. Howev… (show all)

er, in accordance with FAR 5.207 (c) (16) (ii), all responsible sources that feel they can meet the Government s requirements detailed above may submit a capability statement which shall be considered by the agency. Responses to this notice shall contain sufficient information to establish the interested parties bona-fide capabilities for fulfilling the requirement and include: the System for Award Management (SAM) Unique Entity ID (UEI), and the Taxpayer Identification Number (TIN), along with documentation that the vendor is an authorized distributor/reseller. All offerors must have an active registration in SAM at www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information will be retained as Market Research. All responses must be received by 12:00 PM Central Time on Thursday, January 9, 2025. Responses shall be submitted electronically to Alisha Milander via email at Alisha.Milander@va.gov. Fax responses and Telephone inquiries will not be accepted.

Who won similar work

6 award notices on SAM.gov in the last 24 months. Matched by: Same office (NETWORK CONTRACT OFFICE 23 (36C263)), same product/service code (PSC) 6550 and NAICS 325413.

Single-winner award sizes (6): middle half $268K to $431K, median $325K; range $124K to $771K.

WinnerAwardsValueLast
BIOMERIEUX INC2$650KOct 1, 2026
MICROGENICS CORPORATION · $TMO · $42.9B1$771KDec 5, 2024
GRIFOLS DIAGNOSTIC SOLUTIONS INC.1$452KOct 21, 2025
Roche Diagnostics Minneapolis MN 55417 USA1$263KJun 21, 2026
PROMEGA CORPORATION1$124KJun 1, 2026

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

Investor context
  • $TMO reported $42.9B revenue in FY2025. The median single-winner award in these 6 past awards, $325K, is under 0.1% of that. 10-K

One award's total value against one year of revenue; many awards are paid over several years.

Latest awards

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 5 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 2 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (7 filings)
  • 0 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
  • $40K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Veterans' Affairs, Senate Committee on Appropriations, Senate Committee on Veterans' Affairs
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 7 bills named on the past winners' lobbying filings
  • 25 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 1 of the past winners are listed companies
  • 0 insider buys and 7 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.